Evidence map›Paper›PMID 40148486›Full record

ArticleScientific reports2025

Multi-strategy enterprise development optimizer for numerical optimization and constrained problems.

Xinyu Cai, Weibin Wang, Yijiang Wang

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xinyu CaiCollege of Business, Jiaxing University, Jiaxing, 314001, China.
Weibin WangCollege of Business, Jiaxing University, Jiaxing, 314001, China. 00008227@zjxu.edu.cn.
Yijiang WangSchool of Labor and Human Resources, Renmin University of China, Beijing, 100872, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enterprise Development Optimizer (EDO) is a meta-heuristic algorithm inspired by the enterprise development process with strong global search capability. However, the analysis of the EDO algorithm shows that it suffers from the defects of rapidly decreasing population diversity and weak exploitation ability when dealing with complex optimization problems, while its algorithmic structure has room for further enhancement in the optimization process. In order to solve these challenges, this paper proposes a multi-strategy enterprise development optimizer called MSEDO based on basic EDO. A leader-based covariance learning strategy is proposed, aiming to strengthen the quality of search agents and alleviate the weak population diversity of the EDO algorithm in the later search stage through the guiding role of the dominant group and the modifying role of the leader. To dynamically improve the local exploitation capability of the EDO algorithm, a fitness and distance-based leader selection strategy is proposed. In addition, the structure of EDO algorithm is reconstructed and a diversity-based population restart strategy is presented. The strategy is utilized to assist the population to jump out of the local optimum when the population is stuck in search stagnation. Ablation experiments verify the effectiveness of the strategies of the MSEDO algorithm. The performance of the MSEDO algorithm is confirmed by comparing it with five different types of basic and improved metaheuristic algorithms. The experimental results of CEC2017 and CEC2022 show that MSEDO is effective in escaping from local optimums with its favorable exploitation and exploration capabilities. The experimental results of ten engineering constrained problems show that MSEDO has the ability to competently solve real-world complex optimization problems.

Indexed as

CEC2017CEC2022Engineering optimization problemsEnterprise development optimizerMetaheuristic algorithmsRestart strategy

Identifiers

PMID40148486
PMCPMC11950178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.